SCHEMBL806532

SCHEMBL806532

Cc1ccc(C)c2[nH]ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFB P00751 5/20 0.40
CYP1A2 P05177 2/20 0.39
CCR8 P51685 1/20 0.37
GOT1 P17174 1/20 0.37
AXL P30530 1/20 0.36
PRKCI P41743 1/20 0.36
KMT2A Q03164 3/20 0.36
TRIM24 O15164 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
BRPF1 P55201 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
GLA P06280 2/20 0.33
CYP3A4 P08684 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
HTR2A P28223 1/20 0.33
CYP2A6 P11509 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24872829 0.83 OPRK1 (0.39) CFBCYP1A2CCR8AXLPRKCI
SCHEMBL6870752 0.81 TNF (0.39) CFBCCR8GOT1AXLPRKCI
SCHEMBL265821 0.81 AHR (0.42) CFBCCR8GOT1AXLPRKCI
SCHEMBL8913181 0.81 KDM4E (0.38) CFBCYP1A2CCR8GOT1AXL
SCHEMBL24810964 0.81 CFB (0.36) CFBCCR8GOT1AXLPRKCI
SCHEMBL2768928 0.81 DRD4 (0.39) CFBCYP1A2CCR8AXLPRKCI
SCHEMBL6870400 0.81 AXL (0.40) CFBCYP1A2CCR8GOT1AXL
SCHEMBL806287 0.81 TNF (0.39) CFBCYP1A2CCR8AXLPRKCI
SCHEMBL2983820 0.81 ALDH1A1 (0.38) CFBCYP1A2CCR8AXLPRKCI
SCHEMBL1465882 0.81 AHR (0.42) CFBCYP1A2CCR8AXLPRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250342-B1 BRIDGED METALLOCENE COMPOUNDS AS OLEFIN-POLYMERIZATION CATALYSTS POLIMERI EUROPA SPA (IT) 2006-06-28 EP claimed
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-12-12 US disclosed
WO-2023072962-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2023-05-04 WO disclosed
US-20230128137-A1 BENZO FIVE-MEMBERED CYCLIC COMPOUND MEDSHINE DISCOVERY INC. (CN) 2023-04-27 US disclosed
US-20230128137-A1 BENZO FIVE-MEMBERED CYCLIC COMPOUND MEDSHINE DISCOVERY INC. (CN) 2023-04-27 US disclosed
EP-4129989-A1 NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF Haisco Pharmaceuticals Pte. Ltd. (SG) 2023-02-08 EP disclosed
US-11193065-B2 Liquid crystal composition, method of producing the same, and retardation film constituted from the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-12-07 US disclosed
CN-112047870-B Preparation method of 7-alkyl indole derivative 浙江工业大学 2021-10-12 CN disclosed
EP-3464286-B1 PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER GENENTECH INC (US) 2021-08-18 EP disclosed
EP-3397637-B1 COMPOUND FOR PHOTOACTIVE ORGANIC ELECTRONIC ELEMENT, AND PHOTOACTIVE ORGANIC ELECTRONIC ELEMENT COMPRISING THE COMPOUND HELIATEK GMBH (DE) 2021-08-11 EP disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 US disclosed
US-20070161645-A1 Thiazole inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-07-12 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
WO-2007056023-A2 THIAZOLE INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 WO disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 WO disclosed
EP-0734386-B1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES ABBOTT LAB (US) 2002-02-06 EP disclosed
US-6239062-B1 ORGANOMETALLIC COMPOUND OF A GROUP 3 TO 10 TRANSITION OR LANTHANIDE METAL AND A MULTIDENTATE LIGAND CHARACTERIZED BY AN INDOLYL GROUP LINKED TO AN AMIDO GROUP, WHERE THE INDOLYL IS PI-BONDED AND THE AMIDO GROUP IS SIGMA BONDED TO THE METAL EQUISTAR CHEMICALS, L.P. 2001-05-29 US disclosed
EP-0734386-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES Abbott Laboratories (US) 1996-10-02 EP disclosed
US-5486525-A ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1996-01-23 US disclosed
WO-1995016687-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES ABBOTT LABORATORIES (US) 1995-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 CFB 2699/4885CYP1A2 124/4885CCR8 2285/4885
US-20230128137-A1 BENZO FIVE-MEMBERED CYCLIC COMPOUND BCL2, BAX, BCL2L1 CFB 2608/4885CYP1A2 3838/4885CCR8 3989/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 CFB 4575/4885CYP1A2 1622/4885CCR8 1165/4885
US-20070161645-A1 Thiazole inhibitors targeting resistant kinase mutations JAK2, ABL1, FLT3 CFB 4733/4885CYP1A2 3071/4885CCR8 2235/4885
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR CFB 4645/4885CYP1A2 1726/4885CCR8 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.